Association of British Clinical Diabetologists (ABCD) position statement on the risk of diabetic ketoacidosis associated with the use of sodium-glucose cotransporter-2 inhibitors
被引:8
|
作者:
Dashora, Umesh
论文数: 0引用数: 0
h-index: 0
机构:
Conquest Hosp, Hastings, EnglandConquest Hosp, Hastings, England
[4] East & North Herts NHS Trust, Stevenage, Herts, England
来源:
BRITISH JOURNAL OF DIABETES
|
2016年
/
16卷
/
04期
关键词:
SGLT-2;
inhibitors;
diabetic ketoacidosis;
ABCD;
D O I:
10.15277/bjd.2016.112
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Diabetic Ketoacidosis (DKA) has been reported in patients with diabetes taking SGLT-2 inhibitor drugs both in clinical trials and in real life situations, particularly amongst patients taking insulin. The US Food and Drug Administration (FDA) has issued a safety communication following 20 cases of DKA in patients receiving these drugs. 1 This concern has also prompted an American Association of Clinical Endocrinologists and American College of Endocrinology position statement covering the use of SGLT-2 inhibitors in people with type 2 diabetes. 2 The following is the ABCD position statement on this issue.
机构:
Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
Univ Toronto, Dept Med, Div Nephrol, Toronto Gen Hosp, Toronto, ON, CanadaUniv Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
Heerspink, Hiddo J. L.
Kosiborod, Mikhail
论文数: 0引用数: 0
h-index: 0
机构:
St Lukes Mid Amer Heart Inst, Kansas City, MO USA
Univ Missouri, Kansas City, MO 64110 USA
Univ Toronto, Dept Med, Div Nephrol, Toronto Gen Hosp, Toronto, ON, CanadaUniv Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands
机构:
Univ Toronto, Dept Med, Div Nephrol, Toronto Gen Hosp, Toronto, ON, CanadaUniv Groningen, Univ Med Ctr Groningen, Dept Clin Pharm & Pharmacol, Groningen, Netherlands